Related Experiment Videos
Pharmacologic closure of patent ductus arteriosus in the premature infant
Insights
Indomethacin, a prostaglandin synthesis inhibitor, effectively closed the patent ductus arteriosus in premature infants with respiratory-distress syndrome. This pharmacological approach offers a promising alternative to surgery for this common neonatal complication.
Area of Science:
- Neonatal Medicine
- Pediatric Cardiology
- Pharmacology
Background:
- Prostaglandins play a crucial role in maintaining the smooth-muscle tone of the ductus arteriosus.
- Patent ductus arteriosus (PDA) is a frequent complication in premature infants, particularly those with respiratory-distress syndrome (RDS).
- Surgical ligation is a common treatment for PDA in neonates, carrying inherent risks.
Purpose of the Study:
- To evaluate the efficacy of indomethacin, a prostaglandin synthesis inhibitor, in treating PDA in premature infants with RDS.
- To assess the potential of pharmacological intervention as an alternative to surgical closure of PDA.
- To determine the clinical, echocardiographic, and radiographic outcomes following indomethacin administration.
Main Methods:
- A single oral or rectal dose of indomethacin was administered to six consecutive premature infants diagnosed with PDA and RDS.
- Infants were selected who were candidates for surgical ligation prior to the study.
- Clinical symptoms, physical examination, echocardiography, and radiography were used to assess PDA closure and overall condition.
Main Results:
- Within 24 hours of indomethacin administration, all clinical and diagnostic signs of significant left-to-right shunting through the PDA resolved permanently.
- Indomethacin successfully induced constriction and closure of the patent ductus arteriosus in all treated infants.
- A transient reduction in renal function was noted in two infants, with no sustained adverse effects.
Conclusions:
- Pharmacological closure of PDA using indomethacin is a highly effective treatment in premature infants with respiratory-distress syndrome.
- Indomethacin offers a viable and less invasive alternative to surgical ligation for PDA in this vulnerable population.
- This approach holds significant potential for improving the management and outcomes of premature infants suffering from PDA and RDS.
Abstract:
The prostaglandins affect smooth-muscle tone of the ductus arteriosus. Patent ductus often complicates the clinical course of prematurely born infants with respiratory-distress syndrome. In the present study, a single oral or rectal dose of a potent inhibitor of prostaglandin synthesis, indomethacin, was administered to six consecutive premature infants with the syndrome who would otherwise have undergone surgical ligation of the patent ductus. Within 24 hours all the clinical symptoms and physical, echocardiographic and radiographic signs attributable to substantial left-to-right shunting through a patent ductus arteriosus dramatically and permanently disappeared. A transient reduction in renal function was observed in two infants in whom sustained ill-effects did not occur. The observation that constriction and closure of the patent ductus arteriosus may be induced pharmacologically raises important possibilities for the improved treatment of the respiratory-distress syndrome.